3.7. Notices. All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified; (b) upon confirmation of receipt when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient; if not, then on the next business day; (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the party to be notified at the address as set forth on the signature pages hereof or Exhibit A hereto or at such other address or electronic mail address as such party may designate by ten (10) days advance written notice to the other parties hereto; provided that, in the case of the Company, notice shall be provided to Metagenomi Inc., 1545 Park Avenue, Emeryville, CA 94608, Attn: Brian Thomas, Chief Executive Officer, and a copy (which copy shall not constitute notice) shall also be sent to .
3.8. Attorneys’ Fees. In the event that any suit or action is instituted under or in relation to this Agreement, including without limitation to enforce any provision in this Agreement, the prevailing party in such dispute shall be entitled to recover from the losing party all fees, costs and expenses of enforcing any right of such prevailing party under or with respect to this Agreement, including without limitation, such reasonable fees and expenses of attorneys and accountants, which shall include, without limitation, all fees, costs and expenses of appeals.
3.9. Titles and Subtitles. The titles of the sections and subsections of this Agreement are for convenience of reference only and are not to be considered in construing this Agreement.
3.10. Non-Use of Name. Without the prior written consent of Bayer Healthcare LLC (“Bayer”), Frazier Life Sciences Public Fund, L.P. (“Frazier”), MW XO Health Innovations Fund, LP (“MW”), RA Capital Healthcare Fund, L.P. (“RA”), Citadel CEMF Investments Ltd. (“Surveyor”), Pura Vida Investments, LLC (“Pura Vida”), Tencent Holdings Ltd. or any of its Affiliates (collectively, the “Tencent Group”), Bristol-Myers Squibb Company (“BMS”), Novo Holdings A/A and/or its Affiliates (“Novo”), MTGNM Delaware LLC (“MTGNM”), PFM Healthcare Master Fund, L.P., PFM Healthcare Growth Equity Fund I, LP, and PFM Meta LP and their Affiliates (collectively, “PFM”), and Farallon, each party (other than Bayer, Frazier, MW, RA, Surveyor, Pura Vida, Tencent Group, BMS, Novo, MTGNM, PFM and Farallon, in each case, solely with respect to such party itself) shall not, and shall cause its Affiliates not to, use, publish, reproduce, or refer to the respective trade names of Bayer, Frazier, MW, RA, Surveyor, Pura Vida, Tencent Group, BMS, Novo, MTGNM, PFM and Farallon or any of their respective Affiliates, its related parties, controlling persons, or any similar name, trademark or logo, in each case, as applicable, in any non-internal discussion, documents or materials, including without limitation for marketing, advertising, publicity or other purposes.
3.11. Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument.
17